News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
恒瑞醫藥(01276.HK)SHR-3079注射液獲批臨床
恒瑞醫藥(01276.HK)公布，子公司蘇州盛迪亞生物醫藥收到國家藥監局核准簽發關於SHR-3079注射液《藥物臨床試驗批准通知書》，將於近期開展臨床試驗。SHR-3079注射液是公司自主研發的創新型抗腫瘤藥物，擬用於治療B細胞非霍奇金淋巴瘤。(ha/da)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
恒瑞醫藥(01276.HK)SHR-3079注射液獲批臨床
Close
Recommend
4
Positive
5
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

恒瑞醫藥(01276.HK)  -1.050 (-1.683%)    Short selling $39.38M; Ratio 19.628%   公布，子公司蘇州盛迪亞生物醫藥收到國家藥監局核准簽發關於SHR-3079注射液《藥物臨床試驗批准通知書》，將於近期開展臨床試驗。SHR-3079注射液是公司自主研發的創新型抗腫瘤藥物，擬用於治療B細胞非霍奇金淋巴瘤。(ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.